Trial Profile

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Apr 2025 According to a Larimar Therapeutics media release, the company announced completion of dosing of adolescents (12-17 years of age) in a PK run-in study for pediatric patients with FA
24 Mar 2025 According to a Larimar Therapeutics media release, the company expect to complete the dosing of the adolescent cohort by the end of this month and report available data in September 2025.
23 Jan 2025 According to a Larimar Therapeutics media release, the long-term data is expected mid-2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com